The role of plaque rupture and thrombosis in coronary artery disease

Atherosclerosis

Volumn 149, Issue 2, 2000, Pages 251-266

  Zaman, A G ^a   Helft, G ^a   Worthley, S G ^a   Badimon, J J ^a  

^a Cardiovasc Biol Res Laboratory   (United States)

Author keywords

Atherosclerosis; Coronary artery; Plaque rupture; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; CLOPIDOGREL; COLONY STIMULATING FACTOR 1; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; OXIDIZED LOW DENSITY LIPOPROTEIN; THROMBOPLASTIN; TICLOPIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WARFARIN;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DISEASE COURSE; FOAM CELL; HUMAN; LIPID STORAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHEAR STRESS; THEORY; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 0034015006     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00479-7     Document Type: Review

References (160)

1. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 1. New Engl. J. Med. 326(4):1992;242-250.
2. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 2. New Engl. J. Med. 326(5):1992;310-318.
3. Von Rokitansky C. A Manual of Pathological Anatomy. 4:1852;261 Syndheman Soc, Berlin.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
5. Bini A, Fenoglio JJ, Mesa-Tejada, et al. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis. Arteriosclerosis 1989;9:109-121.
6. Anitschow N., Chalatow S. Uber experimentelle Cholesterinstectase und ihre Bedeutung fur die Entstehung einiger pathologischer Prozesse. Centralbl. Allg. Path. Anot. 1:1913;24.
7. Badimon J.J., Fuster V., Chesebro J., Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 87(Suppl. II):1993;3-16.
8. Fuster V., Lewis A. Conner Memorial Lecture, mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
9. Vanhoutte P.M. Endothelium and control of vascular function: state of the art lecture. Hypertension. 13:1989;658-667.
10. Rubanyi G.M. The role of endothelium in cardiovascular homeostasis and diseases. J. Cardiovasc. Pharmacol. 4(Suppl.):1993;S1-S14.
11. Traub O., Berk B.C. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler. Thromb. Vasc. Biol. 18:1998;677-685.
12. Davies P.F. Flow-mediated endothelial mechanotransduction. Physiol. Rev. 75:1995;519-560.
13. Ku D.N., Giddens D.P., Zarins C.K., Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation: positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis. 5:1985;293-302.
14. Ross R., Masuda J., Raines E.W., Gown A.M., Katsuda S., Sasahara M., Malden L.T., Masuko H., Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 248:1990;1009-1012.
15. Topper J.N., Cai J., Falb D., Gimbrone M.A. Jr Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA. 93:1996;10417-10422.
16. Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med. 340(2):1999;115-126.
17. Griendling K.K., Alexander R.W. Oxidative stress and cardiovascular disease. Circulation. 96:1997;3264-3265.
18. Navab M., Berliner J.A., Watson A.D. et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
19. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:1997;20963-20966.
20. Han J., Hajjar D.P., Febbraio M., Nicholson A.C. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J. Biol. Chem. 272:1997;21654-21659.
21. Diaz M.N., Frei B., Vita J.A., Keaney J.F. Jr Antioxidants and atherosclerotic heart disease. New Engl. J. Med. 337:1997;408-416.
22. Stary H.C. Composition and classification of human atherosclerotic lesions. Virchows Arch. A Pathol. Anat. Histopathol. 421:1992;277-290.
23. Richardson P., Davies M., Born G. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
24. Davies M.J., Woolf N., Rowles P., Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br. Heart J. 60:1988;459-464.
25. Stary H.C., Chandler A.B., Dinsmore R.E. et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis. American Heart Association. Circulation. 92:1995;1355-1374.
26. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am. J. Cardiol. 68:1991;28B-35B.
27. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation. 92:1995;657-671.
28. Gertz S.D., Roberts W.C. Hemodynamic shear force in rupture of coronary arterial atherosclerotic plaques. Am. J. Cardiol. 66:1990;1368-1372.
29. Stary H.C. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis. 9(Suppl. I):1989;19-32.
30. Davies M.J. A macro and micro view of coronary vascular insult in ischaemic heart disease. Circulation. 82(Suppl. II):1990;38-46.
31. Fernandez-Ortiz A., Badimon J., Falk E., Fuster V., Meyer B., Mailhac A., Weng D., Shah P.K., Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J. Am. Coll. Cardiol. 23:1994;1562-1569.
32. Toschi V., Gallo R., Lettino M., Fallon J.T., Fernandez-Ortiz A., Badimon L., Chesebro J.H., Nemerson Y., Fuster V., Badimon J.J. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 95:1997;594-599.
33. Davies M.J., Thomas A.C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br. Heart J. 53:1985;363-373.
34. Moise A., Lesperance J., Theroux P., Taeymans Y., Goulet C., Bourassa M.G. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 non-operated patients. Am. J. Cardiol. 54:1984;1176-1181.
35. Ambrose J.A., Winters S.L., Arora R.R., Eng A., Riccio A., Gorlin R., Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J. Am. Coll. Cardiol. 7:1986;472-478.
36. Giroud D., Li J.M., Urban P., Meier B., Rutishauser W. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am. J. Cardiol. 69:1992;729-732.
37. Ambrose J.A., Tannenbaum M.A., Alexopoulos D., Hjemdahl-Monson C.E., Leavy J., Weiss M., Borrico S., Gorlin R., Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 12:1988;56-62.
38. Little W.C., Constantinescu M., Applegate R.J., Kutcher M.A., Burrows M.T., Kahl F.R., Santamore W.P. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation. 78:1988;1157-1166.
39. Levin D., Fallon J.T. Significance of the angiographic morphology of localized coronary stenosis: histopathologic correlations. Circulation. 66:1982;316-320.
40. Brown B.G., Gallery C.A., Badger R.S., Kennedy J.W., Bolson E.L., Dodge H.T. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation. 73:1986;653-661.
41. Roberts W.C., Buja L.M. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsy patients. Am. J. Med. 52:1972;425-443.
42. Ridolfi R.L., Hutchins G.M. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am. Heart J. 93:1977;468-486.
43. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 71:1985;699-708.
44. Davies M.J., Richardson P.D., Woolf N., Katz D.R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage and smooth muscle cell content. Br. Heart J. 69:1993;377-381.
45. Richardson P.D., Davies M.J., Born G.V.R. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 2:1989;941-944.
46. Small D.M. George Lyman Duff Memorial Lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arteriosclerosis. 8:1988;103-129.
47. Wagner W.D., St Clair R.W., Clarkson T.B., Connor J.R. A study of atherosclerosis regression in Macaca mulatta III: chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Am. J. Pathol. 100:1980;633-650.
48. Loree H.M., Kamm R.D., Stringfellow R.G., Lee R.T. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ. Res. 71:1992;850-858.
49. Bouch D.C., Montgomery G.L. Cardiac lesions in fatal cases of recent myocardial ischaemia from a coronary care unit. Br. Heart J. 32:1970;795-803.
50. Poston R.N., Haskard D.O., Coucher J.R., Gall N.P., Johnson-Tidey R.R. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am. J. Pathol. 140:1992;665-673.
51. Hangartner J.R.W., Charleston A.J., Davies M.J., Thomas A.C. Morphological characteristics of clinically significant coronary artery stenosis in stable angina. Br. Heart J. 56:1986;501-508.
52. Geng Y.J., Wu Q., Muszynski M., Hansson G.K., Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. 16:1996;19-27.
53. Isner J.M., Kearney M., Bortman S., Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 91:1995;2703-2711.
54. Lee R.T., Grodzinsky A.J., Frank E.H., Kamm R.D., Schoen F.J. Structure dependent dynamic mechanical behaviour of fibrous caps from human atherosclerotic plaques. Circulation. 83:1991;1764-1770.
55. Falk E. Why do plaques rupture? Circulation. 86(Suppl. III):1992;30-42.
56. Lendon C.L., Davies M.J., Born G.V.R., Richardson P.D. Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis. 87:1991;87-90.
57. van der Wal A., Becker A., van der Loos C., Das P. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 89:1994;36-44.
58. Constaninides P. Plaque fissures in human coronary thrombosis. J. Atheroscler. Res. 6:1966;1-17.
59. Moreno P.R., Falk E., Palacios I.F., Newell J.B., Fuster V., Fallon J.T. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 90:1994;775-778.
60. Gotlieb A.I., Langille B.L. The role of rheology in atherosclerotic coronary artery disease. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1:1996;595-606 Lippincott-Raven, Philadelphia, PA.
61. Springer T.A., Cybulsky M.I. Traffic signals on endothelium for leukocytes in health, inflammation and atherosclerosis. Fuster V., Ross R., Topol E.J. Atherosclerosis and Coronary Artery Disease. 1:1996;511-538 Lippincott-Raven, Philadelphia, PA.
62. Muller W.A., Weigl S.A., Deng X., Phillips D.M. PECAM-1 is required for transendothelial migration of leukocytes. J. Exp. Med. 178:1993;449-460.
63. Giachelli C.M., Lombardi D., Johnson R.J., Murray C.E., Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152:1998;353-358.
64. Stopeck A.T., Nicholson A.C., Mancini F.P., Hajjar D.P. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J. Biol. Chem. 168:1993;17489-17494.
65. Nagel T., Resnick N., Atkinson W.J., Dewey C.F. Jr, Gimbrone M.A. Jr Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J. Clin. Invest. 94:1994;885-891.
66. Resnick M., Collins T., Atkinson W., Bonthron D.T., Dewey C.F. Jr, Gimbrone M.A. Jr Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear stress responsive element. Proc. Natl. Acad. Sci. USA. 90:1993;4591-4595.
67. Lin M.C., Almus-Jacobs F., Chen H.H., Parry G.C., Mackman N., Shyy J.Y., Chien S. Shear stress induction of the tissue factor gene. J. Clin. Invest. 99:1997;737-744.
68. Mondy J.S., Linder V., Miyashiro J.K., Berk B.C., Dean R.H., Geary R.L. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ. Res. 81:1997;320-327.
69. Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life, Eur Heart J 1990;Suppl. E:3-19.
70. Tracy R.E., Devaney K., Kissling G. Characteristics of the plaque under a coronary thrombus. Virchows Arch. A Pathol. Anat. Histopathol. 405:1985;411-427.
71. Guyton J.R., Black B.I., Seidel C.L. Focal toxicity of oxysterols in vascular smooth muscle cell culture: a model for the atherosclerotic core region. Am. J. Pathol. 137:1990;425-434.
72. Isner J.M., Donaldson R.F., Fortin A.H., Tischler A., Clarke R.H. Attenuation of the media of coronary arteries in advanced atherosclerosis. Am. J. Cardiol. 58:1986;937-939.
73. Matrisian L.M. The matrix degrading metalloproteinases. Bioessays. 14:1992;455-463.
74. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
75. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., Amento E., Libby P. Cytokine stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extra cellular matrix digestion. Circ. Res. 75:1994;181-189.
76. Saren P., Welgus H.G., Kovanen P.T. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157:1996;4159-4165.
77. Mach F., Schonbeck U., Bonnefoy J.-Y. et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin and tissue factor. Circulation. 96:1997;396-399.
78. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. New Engl. J. Med. 336:1997;973-979.
79. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:1997;462-466.
80. Toss H., Lindahl B., Siegbahn A., Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease, FRISC Study Group, fragmin during instability in coronary artery disease. Circulation. 96:1997;4204-4210.
81. Schonbeck U., Mach F., Sukhova G.K., Murphy C., Bonnefoy J.Y., Fabunmi R.P., Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signalling in plaque rupture? Circ. Res. 81:1997;448-454.
82. Shah P.K., Falk E., Badimon J.J., Fernandez-Ortiz A., Mailhac A., Levy G., Fallon J.T., Regnstrom J., Fuster V. Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix degrading metalloproteinases and implications for plaque rupture. Circulation. 92:1995;1565-1569.
83. Henney A.M., Wakeley P.R., Davies M.J., Foster K., Hembry R., Murphy G., Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in-situ hybridization. Proc. Natl. Acad. Sci. USA. 88:1991;8154-8158.
84. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1994;2493-2503.
85. Brown D.L., Hibbs M.S., Kearney M., Loushin C., Isner J.M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation. 91:1995;2125-2131.
86. Sukhova G.K., Shi G.P., Simon D.I., Chapman H.A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102:1998;576-583.
87. Kornbluth R.S. The immunological potential of apoptotic debris produced by tumor cells and during HIV infection. Immunol. Lett. 43:1994;125-132.
88. Bombeli T., Karsan A., Tait J.F., Harlan J.M. Apoptotic vascular endothelial cells become procoagulant. Blood. 89:1997;2429-2442.
89. Flynn P.D., Byrne C.D., Baglin T.P., Weissberg P.L., Bennet M.R. Thrombin generation by apoptotic vascular smooth muscle cells. Blood. 89:1997;4378-4384.
90. Mallat Z., Hugel B., Ohan J., Leseche G., Freyssinet J., Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation. 99:1999;348-353.
91. Atkinson J.B., Harlan C.W., Harlan G.C., Virmani R. The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum. Pathol. 25:1994;154-159.
92. Jonasson L., Skalli O., Bondjers G., Hansson G.K. Regional accumulations of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 6:1986;131-138.
93. Kaartinen M., Penttil A., Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation. 90:1994;1669-1678.
94. Weiss S.J. Tissue destruction by neutrophils. New Engl. J. Med. 320:1989;365-376.
95. Cheng G., Loree H., Kamm R., Fishbein M., Lee R. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation. 87:1993;1179-1187.
96. Davies M.J. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation. 94:1996;2013-2020.
97. Farb A., Burke A.P., Malcolm G.T., Liang Y., Mannan P., Smialek J., Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New Engl. J. Med. 336:1997;1276-1282.
98. Farb A., Burke A.P., Tang A.L., Liang Y., Mannan P., Smialek J., Virmani R. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation. 93:1996;1354-1363.
99. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am. J. Cardiol. 63:1989;114E-120E.
100. Mailhac A., Badimon J.J., Fallon J.T., Fernandez-Ortiz A., Meyer B., Chesebro J.H., Fuster V., Badimon L. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution of fibrin(ogen) and platelets. Circulation. 90:1994;988-996.
101. Davies M., Thomas A., Knapman P., Hangartner R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischaemic cardiac death. Circulation. 73:1986;418-427.
102. Fulton F.M. Pathological concepts in acute coronary thrombosis: relevance to treatment. Br. Heart J. 70:1993;403-408.
103. Rowsell H.C., Hegardt B., Downie H.G., Mustard J.F., Murphy E.A. Adrenaline and experimental thrombosis. Br. J. Haematol. 12:1966;66-73.
104. Mueller J.E., Stone P.H., Turi Z.G., Rutherford J.D., Czeisler C.A., Parker C. et al. The MILIS Study Group: circadian variation in the frequency of onset of acute myocardial infarction. New Engl. J. Med. 313:1985;1315-1322.
105. Tofler G.H., Brezinski D., Schafer A.L., Czeisler C.A., Rutherford J.D., Willich S.N. et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. New Engl. J. Med. 316:1987;1514-1518.
106. Fuster V., Chesebro J.H., Frye R.L., Elveback L. Platelet survival and the development of coronary artery disease in the young adult: effect of cigarette smoking, strong family history and medical therapy. Circulation. 63:1981;546-551.
107. Winniford M.D., Wheelan K.R., Kremers M.S., Ugolini V., van den Berg E. Jr, Niggemann E.H. et al. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation. 73:1986;662-667.
108. Paul O. Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension and selected risk factors. Circulation. 80:1989;206-214.
109. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factor and the risk of myocardial infarction or sudden death in patients with angina pectoris, New Engl J Med 1989;332:635-641.
110. Carvalho A.C., Colman R.W., Lees R.S. Platelet function in hyperlipoproteinemia. New Engl. J. Med. 290:1974;434-438.
111. Knobler H., Savion N., Shenkman B., Kotev-Emeth S., Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb. Res. 90:1998;181-189.
112. Malinow M.R. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation. 81:1990;2004-2006.
113. Dahlen G.H., Guyton J.R., Attar M., Farmer J.A., Kautz J.A., Gotto A.M. Jr Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 74:1986;758-765.
114. Juhan-Vague I., Pyke S.D., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group, European concerted action on thrombosis and disabilities. Circulation. 94:1996;2057-2063.
115. Scarabin P.Y., Aillaud M.F., Amouyel P., Evans A., Luc G., Ferrieres J. et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10 500 male participants in a prospective study of myocardial infarction - the PRIME Study, prospective epidemiological study of myocardial infarction. Thromb. Haemost. 80:1998;749-756.
116. Thiruvikraman S.V., Guha A., Roboz J., Taubman M.B., Nemerson Y., Fallon J.T. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin labeled factors VIIa and X. Lab. Invest. 75:1996;451-461.
117. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., Murcia A.M., Palacios I.F., Gold H.K., Mehran R., Sharma S.K., Nemerson Y., Fuster V., Fallon J.T. Macrophages, smooth muscle cells and tissue factor in unstable angina: implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation. 94:1996;3090-3097.
118. Fuster V., Fallon J.T., Nemerson Y. Coronary thrombosis. Lancet. 348(Suppl. 1):1996;S7-S10.
119. Chesebro J.H., Webster M.W.I., Zoldhelyi P., Roche P.C., Badimon L., Badimon J.J. Antithrombotic therapy and progression of coronary artery disease: antiplatelets versus antithrombins. Circulation. 86(Suppl. III):1992;100-110.
120. McBane R.D. 2nd, Miller R.S., Hassinger N.L., Chesebro J.H., Nemerson Y., Owen W.G. Tissue prothrombin: universal distribution in smooth muscle. Arterioscler. Thromb. Vasc. Biol. 17:1997;2430-2436.
121. Weitz J.I., Hudoba M., Massel D., Moraganore J., Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J. Clin. Invest. 86:1990;385-391.
122. Eisenberg P.R., Siegel J.E., Abendschein D.R., Miletich J.P. Importance of factor Xa in determining the procoagulant activity of whole blood clots. J. Clin. Invest. 91:1993;1877-1883.
123. Bar-Shavit R., Eldor A., Vlodavsky I. Binding of thrombin to subendothelial extracellular matrix: protection and expression of functional properties. J. Clin. Invest. 84:1989;1096-1104.
124. Meyer B.J., Badimon J.J., Mailhac A., Fernandez-Ortiz A., Chesebro J.H., Fuster V., Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: targeting optimal therapy. Circulation. 90:1994;2432-2438.
125. Webster M.W.I., Chesebro J.H., Fuster V. Antithrombotic therapy in acute myocardial infarction: enhancement of re-occlusion and prevention of thromboembolism. Gersh B.J., Rahimtoola S.H. Acute Myocardial Infarction. 1991;331-348 Elsevier, New York.
126. Meyer B.J., Badimon J.J., Chesebro J.H., Fuster V., Fallon J.T., Badimon L. Dissolution of mural thrombus by specific thrombin with r-hirudin: comparison with heparin and aspirin. Circulation. 97:1998;681-685.
127. Davies M., Bland J., Hangartner J., Angelini A., Thomas A. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur. Heart J. 10:1989;203-208.
128. Ambrose J.A., Hjemdahl-Monsen C.E., Borrico S., Gorlin R., Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non Q-wave acute myocardial infarction. Am. J. Cardiol. 61:1988;244-247.
129. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet 1994;344:1383-1389.
130. Gould A.L., Rossouw J.E., Santanello N.C., Heyse J.F., Furberg C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 97:1998;946-952.
131. Blankenhorn D.H., Azen S.P., Kramsch D.M., Mack W.J., Cashin-Hemphill L., Hodis H.N. et al. Coronary angiographic changes with lovastatin therapy, the Monitored Atherosclerosis Regression Study (MARS), the MARS research group. Ann. Intern. Med. 119:1993;969-976.
132. Vaughan C.J., Murph M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
133. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol fed rabbit. J. Clin. Invest. 85:1990;1234-1241.
134. Galis Z.S., Asanuma K., Godin D., Meng X. N-Acetyl-cysteine decreases the matrix degrading capacity of macrophage derived foam cells: new target for antioxidant therapy? Circulation. 97:1998;2445-2453.
135. Aikawa M., Rabkin E., Okada Y., Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 97:1998;2433-2444.
136. Gaziano J.M. Antioxidant vitamins and coronary artery disease risk. Am. J. Med. 97(Suppl. IIIA):1994;18S-21S.
137. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. New Engl. J. Med. 328:1993;1450-1456.
138. Stampfer M.J., Hennekens C.H., Manson J.E., Colditz G.A., Rosner B., Willett W.C. Vitamin E consumption and the risk of coronary disease in women. New Engl. J. Med. 328:1993;1444-1449.
139. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet. 347:1996;781-786.
140. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem D., Kostis J., Benedict C., Rousseau M., Bourassa M., Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
141. Rutherford J, Pfeffer M, Moyt L, Davies B, Flaker G, Kowey P, Lamas G, Miller HS, Packer M, Rouleau J, Braunwald E on behalf of the SAVE Investigators. Effects of captopril on ischemic events after myocardial infarction: results of the Survival and Ventricular Enlargement trial, Circulation 1994;90:1731-1738.
142. The SoLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, New Engl J Med 1991;325:293-302.
143. Wright R.A., Flapan A.D., Alberta K.G., Ludlam C.A., Fox K.A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J. Am. Coll. Cardiol. 24:1994;67-73.
144. Cambien F., Poirier O., Leclerf L., Evans A., Cambou J.P., Arveiler D., Luc G., Bard J.M., Bara L., Ricard S. et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
145. Oike Y., Hata A., Ogata Y., Numata Y., Shido K., Kondo K. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J. Clin. Invest. 96:1995;2975-2979.
146. Manson J.E. Postmenopausal hormone therapy and atherosclerotic disease. Am. Heart J. 128:1994;1337-1343.
147. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittingho E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J. Am. Med. Assoc. 280:1998;605-613.
148. Kjekshus J.K. Importance of heart rate in determining betablocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am. J. Cardiol. 57(Suppl. F):1986;43F-49F.
149. Jonas M.A., Oates J.A., Ockene J., Hennekens C.H. Statement on smoking and cardiovascular disease for health care professionals: American Heart Association medical/scientific statement. Circulation. 86:1992;1664-1669.
150. Lichtlen PR, Nikutta P, Jost S, Deckers J, Wiese B, Rafflenbeul W for the INTACT Study Group. Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography: relation to clinical events and risk factors, Circulation 1992;86:828-838.
151. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., Deanfield J.E. Endothelium dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J. Am. Coll. Cardiol. 24:1994;1468-1474.
152. Glagov S., Weisenberg E., Zarins C.K., Stankunavicius R., Kolettis G.J. Compensatory enlargement of human atherosclerotic coronary arteries. New Engl. J. Med. 316:1987;1371-1375.
153. Skinner M.P., Yuan C., Mitsumori L., Hayes C.E., Raines E.W., Nelson J.A. et al. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat. Med. 1:1995;69-73.
154. Worthley SG, Helft G, Fuster V, Fayad ZA, Fallon JT, Osende JI, Roque M, Shinnar M, Zaman AG, Rodriguez OJ, Verhallen P, Badimon JJ. High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model, Atherosclerosis 2000 (in press).
155. Toussaint J.F., LaMuraglia G.M., Southern J.F., Fuster V., Kantor H.L. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic and thrombotic components of human atherosclerosis in vivo. Circulation. 94:1996;932-938.
156. Gupta S., Leatham E.W., Carrington D., Mendall M.A., Kaski J.C., Camm A.J. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation. 96:1997;404-407.
157. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. Randomised trial of roxithromycin in non Q-wave coronary syndromes: ROXIS Pilot Study, ROXIS Study Group. Lancet. 350:1997;404-407.
158. Kullo I.J., Mozes G., Schwartz R.S., Gloviczki P., Crotty T.B., Barber D.A. et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation. 96:1997;2245-2261.
159. Kullo I.J., Mozes G., Schwartz R.S., Gloviczki P., Tsutsui M., Katusic Z.S. et al. Enhanced endothelium-dependent relaxations after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries. Hypertension. 30:1997;314-320.
160. Zoldhelyi P., McNatt J., Xu X.M., Loose-Mitchell D., Meidell D., Clubb F.J. Jr et al. Prevention of arterial thrombosis by adenovirus mediated transfer of cyclooxygenase gene. Circulation. 93:1996;10-17.